Gossamer Bio Announces Positive First Quarter 2024 Financial Results and Advances in Development of Seralutinib for Pulmonary Hypertension Treatment
SAN DIEGO - Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), has reported its financial results for the first quarter ended March 31, 2024. In addition, the company has provided an update on its business progress.
Gossamer Bio continues to remain steadfast in its mission to enhance the lives of patients suffering from PAH and PH-ILD. The company’s dedication to finding novel treatments is evident as it advances the development of seralutinib, a promising therapeutic option for these debilitating conditions.
In the recently published TORREY Phase 2 study manuscript
Comments